TABLE 3.
Autologous serum neutralization titers of early and late post-X4 virus clones of ACH6052
| Clone | Time since entry (mo)a | Phenotype | Neutralization titer (IC50) at mo since entrya,b
|
||
|---|---|---|---|---|---|
| 0 | 6.8 | 32.1 | |||
| 6052.1G2 | 0 | R5 | <40 | <40 | 50 |
| 6052.1E2 | 0 | R5 | <40 | <40 | <40 |
| 6052.4C4 | 32.1 | R5 | <40 | <40 | <40 |
| 6052.4C3 | 32.1 | R5 | <40 | <40 | <40 |
| 6052.1H4 | 0 | X4 | >1,280 | 339 | >1,280 |
| 6052.1G3 | 0 | X4 | >1,280 | 396 | 288 |
| 6052.4A10 | 32.1 | X4 | <40 | <40 | <40 |
| 6052.4B11 | 32.1 | X4 | <40 | <40 | <40 |
a
Months since entry of patient into HIV+ cohort.
b
Neutralization was determined by 7-day culture of clonal virus isolates on PBMC in the presence or absence of serial dilutions of serum, followed by analysis of p24 production by ELISA. IC50s were determined by linear regression after subtracting the inhibition obtained using human pooled HIV-1-negative serum.